The Battle Against Cellular Aging: A Deep Dive into Senolytics and Epigenetic Reprogramming
At the heart of the longevity market is the battle against cellular aging. Two of the most promising fronts in this war are senolytics and epigenetic reprogramming. Senolytics are a class of drugs that selectively remove "senescent" cells—old, damaged cells that no longer divide but remain in the body, releasing inflammatory signals that drive aging. With a market size of nearly USD 64 million in 2025, the senolytics segment is growing rapidly as companies like Oisin Biotechnologies advance to clinical trials.
Even more groundbreaking is the work in epigenetic reprogramming. Recent studies from Harvard have demonstrated that manipulating the epigenome can reverse signs of aging in mice by "rebooting" cells to a more youthful state. This research suggests that biological age is not fixed and that we may hold the key to resetting our cellular clocks. These scientific breakthroughs are not just extending lifespans; they are rewriting the very rules of aging.